Industry seeks trust and louder voice in HTA evolution, says EFPIA
This article was originally published in Scrip
Executive Summary
The pharmaceutical industry has so far had only narrow input into a European pilot that saw numerous health technology assessment (HTA) bodies work together to assess the relative effectiveness of GlaxoSmithKline's Votrient. With greater collaboration on relative effectiveness edging forward, industry should have a bigger say on how HTA evolves, says EFPIA, the European Federation of Pharmaceutical Industry Associations.